Q-omics provides the consensus-scored ELOCP28 profile across patient tissues and cancer cell-line models. ELOCP28 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ELOCP28 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, ELOCP28 RNA expression shows 10,685 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, THCA, and UVM as cancer lineages where ELOCP28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOCP28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOCP28 survival associations across molecular data types. ELOCP28 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOCP28 RNA expression–survival associations across cancer types. High ELOCP28 expression shows unfavorable associations in UVM, READ and LGG, but favorable associations in ACC, BLCA and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for ELOCP28 RNA expression.
This table summarizes ELOCP28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ELOCP28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOCP28 shows lower tumor expression in THCA, COAD, KIRP, KIRC, KICH and BRCA. The THCA box plot shows higher ELOCP28 RNA expression in normal versus tumor tissue (log2 FC = −0.281, t-test p < 0.001).
This table shows molecular features associated with ELOCP28 in patient tissues and cancer cell lines. In patient samples, ELOCP28 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
